Caribou Biosciences, Inc. (NASDAQ:CRBU – Free Report) – Investment analysts at Leerink Partnrs reduced their FY2025 EPS estimates for Caribou Biosciences in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.77) for the year, down from their prior forecast of ($1.64). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ FY2026 earnings at ($1.84) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at $0.28 EPS.
Other research analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Citigroup decreased their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Finally, Bank of America decreased their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Caribou Biosciences currently has a consensus rating of “Buy” and an average target price of $10.33.
Caribou Biosciences Stock Performance
CRBU stock opened at $1.51 on Friday. The company has a market capitalization of $136.73 million, a PE ratio of -0.92 and a beta of 2.34. Caribou Biosciences has a one year low of $1.47 and a one year high of $8.33. The company’s 50 day moving average price is $1.83 and its two-hundred day moving average price is $1.99.
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Milestone Asset Management LLC increased its stake in shares of Caribou Biosciences by 5.6% in the fourth quarter. Milestone Asset Management LLC now owns 163,789 shares of the company’s stock worth $260,000 after buying an additional 8,662 shares during the period. Thrive Wealth Management LLC purchased a new position in shares of Caribou Biosciences in the fourth quarter worth $51,000. Green Alpha Advisors LLC boosted its holdings in Caribou Biosciences by 75.4% in the fourth quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock valued at $288,000 after acquiring an additional 77,840 shares in the last quarter. Barclays PLC boosted its holdings in Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after acquiring an additional 71,463 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares in the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Further Reading
- Five stocks we like better than Caribou Biosciences
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What is the MACD Indicator and How to Use it in Your Trading
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How to Use Stock Screeners to Find Stocks
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.